NCT01915459View on ClinicalTrials.gov

Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity

PHASE3CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions
StrokeSpasticity
Interventions
BIOLOGICAL

Botulinum toxin type A(Botulax®)

IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone

BIOLOGICAL

Botulinum toxin type A(Botox®)

Trial Locations (6)

Unknown

The Catholic University of Korea Incheon St. Mary's hospital, Incheon

Seoul National University Hospital, Bundang

Asan Medical Center, Seoul

Chung Ang University Hospital, Seoul

Gangnam Severance Hospital, Seoul

SMG-SNU Boramae Medical Center, Seoul

All Listed Sponsors
lead

Hugel

INDUSTRY

NCT01915459 - Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity | Biotech Hunter | Biotech Hunter